Home › Cancro del polmone non a piccole cellule › Oregon › Eugene
Studi clinici su Cancro del polmone non a piccole cellule a Eugene, OR
13 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Eugene e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
In reclutamentoFase 3
- Oncology Associates Of Oregon, Pc, Eugene
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
In reclutamentoFase 3
- Oncology Associates of Oregon PC, Eugene
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
In reclutamentoFase 3
- Oncology Associates of Oregon, P.C., Eugene
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
In reclutamentoFase 2
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
In reclutamentoFase 1/2
- Oncology Associates of Oregon, P.C., Eugene
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
In reclutamentoFase 3
- Clinical Study Site, Eugene
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
In reclutamentoFase 2/3
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- USO - Oncology Associates of Oregon, Eugene
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
In reclutamentoFase 1
- USOR - Oncology Associates of Oregon, P.C, Eugene
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
In reclutamentoFase 2
- Williamette Valley Cancer Institute and Research Center, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
In reclutamentoFase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
In reclutamentoFase 1
- Willamette Valley Cancer Institute and Research Center, Eugene
MYLUNG Consortium Part 3: Observational Study
In reclutamentoStudio osservazionale
- Willamette Valley Cancer Institute and Research Center, Eugene
Studi su Cancro del polmone non a piccole cellule in altre città
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Altri studi a Eugene
- Cancro ovarico9 studi
- Cancro dell'endometrio8 studi
- Cancro al seno7 studi
- Leucemia linfatica cronica6 studi
- Mieloma multiplo6 studi
- Cancro metastatico6 studi
- Cancro (tutti i tipi)6 studi
- Uso di sostanze e dipendenza5 studi
- Cancro ai polmoni5 studi
- Degenerazione maculare5 studi
- Obesità4 studi
- Cancro alla prostata3 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.